Pharma companies receive easy and extremely subsidized access to research that costs almost a hundred billion every year. They don't need to be the direct reci

Pharma companies receive easy and extremely subsidized access to research that costs almost a hundred billion every year. They don't need to be the direct recipients of the grant to be the direct benefactors.